

Andrew H Briggs

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2766940/andrew-h-briggs-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

342
papers

21,624
citations

72
h-index

141
g-index

386
ext. papers

25,517
ext. citations

4.6
avg. IF

6.87
L-index

#	Paper	IF	Citations
342	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Public Health</i> , 2022 , 22, 179	4.1	2
341	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 1-10	1.9	
340	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Health Services Research</i> , 2022 , 22, 114	2.9	2
339	Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>International Journal of Technology Assessment in Health Care</i> , 2022 , 38, e13	1.8	5
338	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Value in Health</i> , 2022 , 25, 3-9	3.3	14
337	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>MDM Policy and Practice</i> , 2022 , 7, 23814683211061097	1.5	
336	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. <i>Health Policy OPEN</i> , 2022 , 3, 100063	1.9	2
335	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMC Medicine</i> , 2022 , 20, 23	11.4	6
334	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Applied Health Economics and Health Policy</i> , 2022 , 20, 213	3.4	1
333	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>European Journal of Health Economics</i> , 2022 , 1	3.6	1
332	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 28, 146-155	1.9	0
331	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Journal of Medical Economics</i> , 2022 , 25, 1-7	2.4	1
330	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.. <i>BMJ, The</i> , 2022 , 376, e067975	5.9	8
329	Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations.. <i>Pharmacoeconomics</i> , 2022 , 1	4.4	1
328	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force.. <i>Value in Health</i> , 2022 , 25, 10-31	3.3	35
327	Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.. <i>Value in Health</i> , 2022 , 25, 230-237	3.3	0
326	Cost-effectiveness of casirivimab/imdevimab in patients with COVID-19 in the ambulatory setting.. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022 , 1-11	1.9	0

325	Modeling Chronic Kidney Disease in Type2 Diabetes Mellitus: A Systematic Literature Review of Models, Data Sources, and Derivation Cohorts.. <i>Diabetes Therapy</i> , 2022 , 13, 651	3.6	
324	Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).. <i>Trials</i> , 2022 , 23, 307	2.8	1
323	The EMPOWER blended digital intervention for relapse prevention in schizophrenia: a feasibility cluster randomised controlled trial in Scotland and Australia.. <i>Lancet Psychiatry</i> , 2022 , 9, 477-486	23.3	2
322	Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT. <i>Health Technology Assessment</i> , 2022 , 26, 1-174	4.4	0
321	Conceptual Framework and Methodological Challenges for Modeling Effectiveness in Oncology Treatment Sequence Models. <i>Pharmacoeconomics</i> , 2021 , 1	4.4	0
320	Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. <i>Pharmacoeconomics</i> , 2021 , 39, 1343-1354	4.4	2
319	From Spreadsheets to Script: Experiences From Converting a Scottish Cardiovascular Disease Policy Model into R. <i>Applied Health Economics and Health Policy</i> , 2021 , 1	3.4	0
318	Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	22
317	Developing a Framework for the Health Technology Assessment of Histology-independent Precision Oncology Therapies. <i>Applied Health Economics and Health Policy</i> , 2021 , 19, 625-634	3.4	0
316	Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3114-3114	2.2	0
315	Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. <i>Health Economics Review</i> , 2021 , 11, 16	2	0
314	Count the cost of disability caused by COVID-19. <i>Nature</i> , 2021 , 593, 502-505	50.4	20
313	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 168-190	9.3	21
312	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021 , 76, 735-750	9.3	46
311	Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin. <i>Pharmacoeconomics</i> , 2021 , 39, 317-330	4.4	3
310	The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data. <i>Journal of Patient-Reported Outcomes</i> , 2021 , 5, 6	2.6	3
309	Stratified medicine using invasive coronary function testing in angina: A cost-effectiveness analysis of the British Heart Foundation CorMicA trial. <i>International Journal of Cardiology</i> , 2021 , 337, 44-51	3.2	0
308	Protocol for an observational cohort study investigating personalised medicine for intensification of treatment in people with type 2 diabetes mellitus: the PERMIT study. <i>BMJ Open</i> , 2021 , 11, e046912	3	0

307	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <i>Pharmacoeconomics</i> , 2021 , 39, 1201-1208	4.4	1
306	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 236-244	3.8	1
305	The thorny issue of value alignment: how development-focused health technology assessment can help find win-win situations for patients and healthcare systems and commercial investors. <i>International Journal of Technology Assessment in Health Care</i> , 2021 , 37, e57	1.8	
304	Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. <i>Health Economics (United Kingdom)</i> , 2021 , 30, 699-707	2.4	25
303	542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients. <i>Annals of Oncology</i> , 2020 , 31, S473-S474	10.3	2
302	Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. <i>Cancers</i> , 2020 , 12,	6.6	7
301	Accurately Reflecting Uncertainty When Using Patient-Level Simulation Models to Extrapolate Clinical Trial Data. <i>Medical Decision Making</i> , 2020 , 40, 460-473	2.5	6
300	Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes: The ODYSSEY OUTCOMES Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2297-2308	15.1	23
299	Sentinel Lymph Node Biopsy for T1b Melanoma: Balancing Prognostic Value and Cost. <i>Annals of Surgical Oncology</i> , 2020 , 27, 5248-5256	3.1	5
298	Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials. <i>PharmacoEconomics - Open</i> , 2020 , 4, 649-655	2.1	0
297	How methodological frameworks are being developed: evidence from a scoping review. <i>BMC Medical Research Methodology</i> , 2020 , 20, 173	4.7	12
296	A different animal? Identifying the features of health technology assessment for developers of medical technologies. <i>International Journal of Technology Assessment in Health Care</i> , 2020 , 1-7	1.8	3
295	Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2020 , 122, 1754-1759	8.7	9
294	Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support. <i>JMIR Research Protocols</i> , 2020 , 9, e15058	2	13
293	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1096-1104	7.3	13
292	Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15638-e15638	2.2	
291	Economic evaluation of culprit lesion only PCI vs. immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: the CULPRIT-SHOCK trial. <i>European Journal of Health Economics</i> , 2020 , 21, 1197-1209	3.6	0
290	Novel risk stratification algorithm for estimating the risk of death in patients with relapsed multiple myeloma: external validation in a retrospective chart review. <i>BMJ Open</i> , 2020 , 10, e034209	3	2

289	Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma. <i>Journal of the American College of Surgeons</i> , 2020 , 231, 547-554.e1	4.4	4
288	Type 2 diabetes remission: 2-year within-trial and lifetime-horizon cost-effectiveness of the Diabetes Remission Clinical Trial (DiRECT)/Counterweight-Plus weight management programme. <i>Diabetologia</i> , 2020 , 63, 2112-2122	10.3	11
287	Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 310	3	3
286	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. <i>Cancer Research</i> , 2020 , 80, 5427-5434	10.1	32
285	Artificial neural network metamodel for sensitivity analysis in a total hip replacement health economic model. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020 , 20, 629-640	2.2	6
284	A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial. <i>Journal of Medical Economics</i> , 2020 , 23, 64-69	2.4	2
283	Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons. <i>ClinicoEconomics and Outcomes Research</i> , 2019 , 11, 551-565	1.7	5
282	Oral versus Intravenous Antibiotics for Bone and Joint Infection. <i>New England Journal of Medicine</i> , 2019 , 380, 425-436	59.2	304
281	Long-term cost and utility consequences of short-term clinically important deterioration in patients with chronic obstructive pulmonary disease: results from the TORCH study. <i>International Journal of COPD</i> , 2019 , 14, 939-951	3	3
280	Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations. <i>Pharmacoeconomics</i> , 2019 , 37, 1129-1138	4.4	34
279	Cardiac Troponin T and Troponin I in the General Population. <i>Circulation</i> , 2019 , 139, 2754-2764	16.7	90
278	Using Nominal Group Technique to Identify Key Attributes of Oncology Treatments for a Discrete Choice Experiment. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319837925	1.5	3
277	Type 2 diabetes remission: economic evaluation of the DiRECT/Counterweight-Plus weight management programme within a primary care randomized controlled trial. <i>Diabetic Medicine</i> , 2019 , 36, 1003-1012	3.5	7
276	Comparison of health state utility estimates from instrument-based and vignette-based methods: a case study in kidney disease. <i>BMC Research Notes</i> , 2019 , 12, 385	2.3	5
275	Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective. <i>Respiratory Medicine</i> , 2019 , 1, 100008	1.6	2
274	Enhancing Health Through Access to Nature: How Effective are Interventions in Woodlands in Deprived Urban Communities? A Quasi-experimental Study in Scotland, UK. <i>Sustainability</i> , 2019 , 11, 3317	3.6	8
273	Methodology of a Novel Risk Stratification Algorithm for Patients with Multiple Myeloma in the Relapsed Setting. <i>Oncology and Therapy</i> , 2019 , 7, 141-157	2.7	2
272	Comparison of Lost Productivity Due to Eculizumab and Ravulizumab Treatments for Paroxysmal Nocturnal Hemoglobinuria in France, Germany, Italy, Russia, Spain, the United Kingdom, and the United States. <i>Blood</i> , 2019 , 134, 4803-4803	2.2	3

271	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 2019 , 4, 108	4.8	4
270	Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT. <i>Health Technology Assessment</i> , 2019 , 23, 1-146	4.4	5
269	3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. <i>Health Technology Assessment</i> , 2019 , 23, 1-88	4.4	13
268	Health impacts of environmental and social interventions designed to increase deprived communities' access to urban woodlands: a mixed-methods study. <i>Public Health Research</i> , 2019 , 7, 1-172	1.7	11
267	A criterion-based approach to systematic and transparent comparative effectiveness: a case study in psoriatic arthritis. <i>Journal of Comparative Effectiveness Research</i> , 2019 , 8, 1265-1298	2.1	2
266	Within-trial cost and 1-year cost-effectiveness of the DiRECT/Counterweight-Plus weight-management programme to achieve remission of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 169-172	18.1	15
265	Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial. <i>American Heart Journal</i> , 2018 , 201, 86-94	4.9	14
264	The feasibility of a randomised controlled trial to compare the cost-effectiveness of palliative cardiology or usual care in people with advanced heart failure: Two exploratory prospective cohorts. <i>Palliative Medicine</i> , 2018 , 32, 1133-1141	5.5	7
263	A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. <i>Pharmacoeconomics</i> , 2018 , 36, 603-612	4.4	9
262	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. <i>Heart</i> , 2018 , 104, 1006-1013	5.1	28
261	'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. <i>European Heart Journal</i> , 2018 , 39, 2546-2550	9.5	53
260	3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , 2018 , 19, 562-578	21.7	93
259	Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. <i>Pharmacoeconomics</i> , 2018 , 36, 1421-1426	4.4	30
258	Long-term weight loss trajectories following participation in a randomised controlled trial of a weight management programme for men delivered through professional football clubs: a longitudinal cohort study and economic evaluation. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2018 , 15, 10	8.4	18
257	Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective. <i>Cost Effectiveness and Resource Allocation</i> , 2018 , 16, 17	2.4	3
256	Comparison between High-Sensitivity Cardiac Troponin T and Cardiac Troponin I in a Large General Population Cohort. <i>Clinical Chemistry</i> , 2018 , 64, 1607-1616	5.5	61
255	Prices For Common Cardiovascular Drugs In The US Are Not Consistently Aligned With Value. <i>Health Affairs</i> , 2018 , 37, 1298-1305	7	4
254	A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists. <i>Journal of Comparative Effectiveness Research</i> , 2018 , 7, 775-784	2.1	1

253	The impact of patient education on consideration of enrollment in clinical trials. <i>Journal of Community and Supportive Oncology</i> , 2018 , 16, e81-e88		5
252	Behavioural activation versus guided self-help for depression in adults with learning disabilities: the BeatIt RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-130	4.4	5
251	Long-term weight loss following a randomised controlled trial of a weight management programme for men delivered through professional football clubs: the Football Fans in Training follow-up study. <i>Public Health Research</i> , 2018 , 6, 1-114	1.7	19
250	Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia. <i>ClinicoEconomics and Outcomes Research</i> , 2018 , 10, 705-713	1.7	7
249	SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1332-1338	8.7	9
248	Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia. <i>ClinicoEconomics and Outcomes Research</i> , 2018 , 10, 715-721	1.7	7
247	Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 1548-1559	27.4	46
246	Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. <i>Respiratory Medicine</i> , 2018 , 145, 130-137	4.6	3
245	Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study. <i>Medical Decision Making</i> , 2017 , 37, 453-468	2.5	17
244	Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model. <i>Medical Decision Making</i> , 2017 , 37, 469-480	2.5	19
243	Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial. <i>Medical Decision Making</i> , 2017 , 37, 340-352	2.5	37
242	Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. <i>Medical Decision Making</i> , 2017 , 37, 367-376	2.5	10
241	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for depression after psychosis: Pilot trial outcomes (ADAPT). <i>Schizophrenia Research</i> , 2017 , 183, 143-150	3.6	20
240	Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT [®] -Lung Test (ECLS): study protocol for a randomized controlled trial. <i>BMC Cancer</i> , 2017 , 17, 187	4.8	35
239	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , 2017 , 130, 24-33	7.4	14
238	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017 , 72, 1297-1305	9.3	101
237	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017 , 20, 397-403	3.3	16
236	Prediction models for exacerbations in different COPD patient populations: comparing results of five large data sources. <i>International Journal of COPD</i> , 2017 , 12, 3183-3194	3	23

235	Protocol for an economic evaluation of the randomised controlled trial of culprit lesion only PCI versus immediate multivessel PCI in acute myocardial infarction complicated by cardiogenic shock: CULPRIT-SHOCK trial. <i>BMJ Open</i> , 2017 , 7, e014849	3	1
234	PATHway I: design and rationale for the investigation of the feasibility, clinical effectiveness and cost-effectiveness of a technology-enabled cardiac rehabilitation platform. <i>BMJ Open</i> , 2017 , 7, e016781 ³		14
233	Comparison of behavioural activation with guided self-help for treatment of depression in adults with intellectual disabilities: a randomised controlled trial. <i>Lancet Psychiatry</i> , 2017 , 4, 909-919	23.3	37
232	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland. <i>Journal of Medical Economics</i> , 2017 , 20, 8-18	2.4	5
231	Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease. <i>Medical Decision Making</i> , 2017 , 37, 440-452	2.5	14
230	Estimation of Survival Probabilities for Use in Cost-effectiveness Analyses: A Comparison of a Multi-state Modeling Survival Analysis Approach with Partitioned Survival and Markov Decision-Analytic Modeling. <i>Medical Decision Making</i> , 2017 , 37, 427-439	2.5	56
229	Modifying Alcohol Consumption to Reduce Obesity (MACRO): development and feasibility trial of a complex community-based intervention for men. <i>Health Technology Assessment</i> , 2017 , 21, 1-150	4.4	4
228	Evaluation of Health in Pregnancy grants in Scotland: a natural experiment using routine data. <i>Public Health Research</i> , 2017 , 5, 1-278	1.7	1
227	A Systematic Review and Network Meta-Analysis to Evaluate the Comparative Efficacy of Interventions for Unfit Patients with Chronic Lymphocytic Leukemia. <i>Advances in Therapy</i> , 2016 , 33, 1814-1830 ⁷	4.1	7
226	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016 , 6, 29	5.2	34
225	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , 2016 , 3, e000371	3	7
224	Analyzing Health-Related Quality of Life in the EVOLVE Trial: The Joint Impact of Treatment and Clinical Events. <i>Medical Decision Making</i> , 2016 , 36, 965-72	2.5	17
223	Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial. <i>American Heart Journal</i> , 2016 , 172, 160-9	4.9	75
222	A parallel group randomised open blinded evaluation of Acceptance and Commitment Therapy for Depression After Psychosis: A Pilot Trial Protocol (ADAPT). <i>Psychosis</i> , 2016 , 8, 143-155	1.2	2
221	Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant: A cost-effectiveness analysis updated with 5-year follow-up data from the pivotal trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 19-19	2.2	1
220	The SCottish Alcoholic Liver disease Evaluation: A Population-Level Matched Cohort Study of Hospital-Based Costs, 1991-2011. <i>PLoS ONE</i> , 2016 , 11, e0162980	3.7	6
219	The Ankle Injury Management (AIM) trial: a pragmatic, multicentre, equivalence randomised controlled trial and economic evaluation comparing close contact casting with open surgical reduction and internal fixation in the treatment of unstable ankle fractures in patients aged over 60 years. <i>Health Technology Assessment</i> , 2016 , 20, 1-158	4.4	52
218	Assessing the impact of restricted follow-up and small sample sizes on survival estimations in prostate cancer using registry data.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 294-294	2.2	1

217	Cost-effectiveness of brentuximab vedotin in relapsed or refractory systemic anaplastic large cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 18-18	2.2	1
216	Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. <i>ClinicoEconomics and Outcomes Research</i> , 2016 , 8, 323-33	1.7	7
215	Are financial incentives cost-effective to support smoking cessation during pregnancy?. <i>Addiction</i> , 2016 , 111, 360-70	4.6	44
214	The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought. <i>Value in Health</i> , 2016 , 19, 921-928	3.3	119
213	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016 , 6, 47	5.2	95
212	A cardiovascular disease policy model: part 2-preparing for economic evaluation and to assess health inequalities. <i>Open Heart</i> , 2016 , 3, e000140	3	4
211	Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. <i>BioDrugs</i> , 2016 , 30, 307-19	7.9	6
210	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 367-374.e2	11.5	95
209	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016 , 19, 800-810	3.3	8
208	Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy. <i>Value in Health</i> , 2016 , 19, 374-82	3.3	8
207	Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report. <i>Value in Health</i> , 2016 , 19, 704-719	3.3	67
206	Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators. <i>Social Science and Medicine</i> , 2016 , 169, 141-148	5.1	9
205	Close Contact Casting vs Surgery for Initial Treatment of Unstable Ankle Fractures in Older Adults: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1455-1463	27.4	61
204	Specifying the target difference in the primary outcome for a randomised controlled trial: guidance for researchers. <i>Trials</i> , 2015 , 16, 12	2.8	47
203	A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. <i>Heart</i> , 2015 , 101, 201-8	5.1	18
202	Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. <i>Value in Health</i> , 2015 , 18, 161-72	3.3	371
201	Reply to Roberts et al.: CHEERS is Sufficient for Reporting Cost-Benefit Analysis, but May Require Further Elaboration. <i>Pharmacoeconomics</i> , 2015 , 33, 535-6	4.4	6
200	Temporal trends and risk factors for readmission for infections, gastrointestinal and immobility complications after an incident hospitalisation for stroke in Scotland between 1997 and 2005. <i>BMC Neurology</i> , 2015 , 15, 3	3.1	6

199	SurgiCal Obesity Treatment Study (SCOTS): protocol for a national prospective cohort study of patients undergoing bariatric surgery in Scotland. <i>BMJ Open</i> , 2015 , 5, e008106	3	4
198	Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. <i>American Heart Journal</i> , 2015 , 170, 951-60	4.9	4
197	Operationalising the capability approach as an outcome measure in public health: The development of the OCAP-18. <i>Social Science and Medicine</i> , 2015 , 142, 68-81	5.1	48
196	Development and validation of a cost-utility model for Type 1 diabetes mellitus. <i>Diabetic Medicine</i> , 2015 , 32, 1023-35	3.5	7
195	Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers. <i>Health Economics (United Kingdom)</i> , 2015 , 24, 481-90	2.4	16
194	Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information. <i>Medical Decision Making</i> , 2015 , 35, 596-607	2.5	12
193	Fractional flow reserve vs. angiography in guiding management to optimize outcomes in non-ST-segment elevation myocardial infarction: the British Heart Foundation FAMOUS-NSTEMI randomized trial. <i>European Heart Journal</i> , 2015 , 36, 100-11	9.5	174
192	Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial. <i>Value in Health</i> , 2015 , 18, 1079-87	3.7	14
191	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015 , 70, 1372-92	9.3	123
190	Fractional flow reserve (FFR) versus angiography in guiding management to optimise outcomes in non-ST segment elevation myocardial infarction (FAMOUS-NSTEMI) developmental trial: cost-effectiveness using a mixed trial- and model-based methods. <i>Cost Effectiveness and Resource Allocation</i> , 2015 , 13, 16	2.4	10
189	Use of low-dose oral theophylline as an adjunct to inhaled corticosteroids in preventing exacerbations of chronic obstructive pulmonary disease: study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 267	2.8	19
188	Oral versus intravenous antibiotic treatment for bone and joint infections (OVIVA): study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 583	2.8	33
187	BEAT-IT: Comparing a behavioural activation treatment for depression in adults with intellectual disabilities with an attention control: study protocol for a randomised controlled trial. <i>Trials</i> , 2015 , 16, 595	2.8	11
186	Hospital expenditure at the end-of-life: what are the impacts of health status and health risks?. <i>PLoS ONE</i> , 2015 , 10, e0119035	3.7	9
185	Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. <i>Journal of Medical Screening</i> , 2015 , 22, 158-64	1.4	35
184	Decision analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. <i>BMJ Open</i> , 2015 , 5, e007925	3	8
183	Toxicity and quality of life data from SCOT: An international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3514-3514	2.2	5
182	How Do Diabetes Models Measure Up? A Review of Diabetes Economic Models and ADA Guidelines. <i>Journal of Health Economics and Outcomes Research</i> , 2015 , 3, 132-152	1.6	12

181	Contrasting associations of insulin resistance with diabetes, cardiovascular disease and all-cause mortality in the elderly: PROSPER long-term follow-up. <i>Diabetologia</i> , 2014 , 57, 2513-20	10.3	22
180	The progressivity of health-care financing in Kenya. <i>Health Policy and Planning</i> , 2014 , 29, 912-20	3.4	30
179	Questionnaire to assess relevance and credibility of modeling studies for informing health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. <i>Value in Health</i> , 2014 , 17, 174-82	3.3	103
178	Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. <i>Value in Health</i> , 2014 , 17, 525-36	3.3	32
177	Projecting long-term graft and patient survival after transplantation. <i>Value in Health</i> , 2014 , 17, 254-60	3.3	12
176	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014 , 44, 304-23	13.6	112
175	Rational allocation of resources available for healthcare: understanding cost effectiveness analyst. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19492	5.4	
174	Improving the transparency of prognosis research: the role of reporting, data sharing, registration, and protocols. <i>PLoS Medicine</i> , 2014 , 11, e1001671	11.6	81
173	Methods for specifying the target difference in a randomised controlled trial: the Difference Elicitation in TriAls (DELTA) systematic review. <i>PLoS Medicine</i> , 2014 , 11, e1001645	11.6	24
172	Evaluation of health in pregnancy grants in Scotland: a protocol for a natural experiment. <i>BMJ Open</i> , 2014 , 4, e006547	3	3
171	Use of methods for specifying the target difference in randomised controlled trial sample size calculations: Two surveys of trialists' practice. <i>Clinical Trials</i> , 2014 , 11, 300-308	2.2	7
170	The "e" in cost-effectiveness analyses. A case study of omalizumab efficacy and effectiveness for cost-effectiveness analysis evidence. <i>Annals of the American Thoracic Society</i> , 2014 , 11 Suppl 2, S105-11	4.7	22
169	Ankle Injury Management (AIM): design of a pragmatic multi-centre equivalence randomised controlled trial comparing Close Contact Casting (CCC) to Open surgical Reduction and Internal Fixation (ORIF) in the treatment of unstable ankle fractures in patients over 60 years. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 79	2.8	11
168	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , 2014 , 15, 69-82	3.6	21
167	Risk stratification for diabetic eye screening. Reply to Stratton I. M. and Aldington S. J. [letter]. <i>Diabetologia</i> , 2014 , 57, 260-1	10.3	1
166	Population ageing and healthcare expenditure projections: new evidence from a time to death approach. <i>European Journal of Health Economics</i> , 2014 , 15, 885-96	3.6	27
165	A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7101-7101	2.2	1
164	A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e17655-e17655	2.2	1

163	Assessing methods to specify the target difference for a randomised controlled trial: DELTA (Difference ELicitation in TriAls) review. <i>Health Technology Assessment</i> , 2014 , 18, v-vi, 1-175	4.4	53
162	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Cost Effectiveness and Resource Allocation</i> , 2013 , 11, 6	2.4	230
161	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMC Medicine</i> , 2013 , 11, 80	11.4	151
160	Predicted impact of extending the screening interval for diabetic retinopathy: the Scottish Diabetic Retinopathy Screening programme. <i>Diabetologia</i> , 2013 , 56, 1716-25	10.3	54
159	Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. <i>Value in Health</i> , 2013 , 16, 231-50	3.3	1264
158	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Pharmacoeconomics</i> , 2013 , 31, 361-7	4.4	90
157	Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. <i>Value in Health</i> , 2013 , 16, 703-19	3.3	174
156	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Value in Health</i> , 2013 , 16, e1-5	3.3	381
155	Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial. <i>American Heart Journal</i> , 2013 , 166, 662-668.e3	4.9	10
154	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>Clinical Therapeutics</i> , 2013 , 35, 356-63	3.5	14
153	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>European Journal of Health Economics</i> , 2013 , 14, 367-72	3.6	136
152	Acknowledging patient heterogeneity in economic evaluation : a systematic literature review. <i>Pharmacoeconomics</i> , 2013 , 31, 111-23	4.4	45
151	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013 , 120, 765-70	3.7	25
150	ISPOR-SMDM task force's recommendations for good modeling practices-reply to letter to the editor by Corro Ramos. <i>Value in Health</i> , 2013 , 16, 1108	3.3	2
149	Time trends in 30 day case-fatality following hospitalisation for asthma in adults in Scotland: a retrospective cohort study from 1981 to 2009. <i>Respiratory Medicine</i> , 2013 , 107, 1172-7	4.6	10
148	The "hazards" of extrapolating survival curves. <i>Medical Decision Making</i> , 2013 , 33, 369-80	2.5	25
147	Inhaler competence in asthma: common errors, barriers to use and recommended solutions. <i>Respiratory Medicine</i> , 2013 , 107, 37-46	4.6	228
146	Prognosis research strategy (PROGRESS) 4: stratified medicine research. <i>BMJ, The</i> , 2013 , 346, e5793	5.9	251

145	Are value of information methods ready for prime time? An application to alternative treatment strategies for NSTEMI patients. <i>International Journal of Technology Assessment in Health Care</i> , 2013 , 29, 435-42	1.8	12
144	Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. <i>PLoS Medicine</i> , 2013 , 10, e10013806		382
143	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>International Journal of Technology Assessment in Health Care</i> , 2013 , 29, 117-22	1.8	191
142	How effective is the Forestry Commission Scotland's woodland improvement programme--'Woods In and Around Towns' (WIAT)--at improving psychological well-being in deprived urban communities? A quasi-experimental study. <i>BMJ Open</i> , 2013 , 3, e003648	3	14
141	A patient-centred approach to estimate total annual healthcare cost by body mass index in the UK Counterweight programme. <i>International Journal of Obesity</i> , 2013 , 37, 1135-9	5.5	22
140	Transcatheter aortic valve implantation for severe aortic stenosis: the cost-effectiveness case for inoperable patients in the United Kingdom. <i>International Journal of Technology Assessment in Health Care</i> , 2013 , 29, 12-9	1.8	15
139	Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. <i>BMJ, The</i> , 2013 , 346, e5595	5.9	310
138	Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. <i>BMJ, The</i> , 2013 , 346, f1049	5.9	659
137	TRANSCATHETER AORTIC VALVE IMPLANTATION FOR SEVERE AORTIC STENOSIS: THE COST-EFFECTIVENESS CASE FOR INOPERABLE PATIENTS IN THE UNITED KINGDOM □ CORRIGENDUM. <i>International Journal of Technology Assessment in Health Care</i> , 2013 , 29, 112-112	1.8	
136	Long-term effects of statin treatment in elderly people: extended follow-up of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>PLoS ONE</i> , 2013 , 8, e72642	3.7	37
135	Spoilt for choice: implications of using alternative methods of costing hospital episode statistics. <i>Health Economics (United Kingdom)</i> , 2012 , 21, 1201-16	2.4	37
134	Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. <i>Medical Decision Making</i> , 2012 , 32, 667-77	2.5	287
133	Mobile phone use for contacting emergency services in life-threatening circumstances. <i>Journal of Emergency Medicine</i> , 2012 , 42, 291-298.e3	1.5	17
132	The cessation in pregnancy incentives trial (CPIT): study protocol for a randomized controlled trial. <i>Trials</i> , 2012 , 13, 113	2.8	17
131	Statistical Issues with Trial Data and Economic Modeling for Cost-Effectiveness Evaluation 2012 , 149-166		
130	Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , 2012 , 130, 1049-62	11.5	383
129	The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies. <i>Health Outcomes Research in Medicine</i> , 2012 , 3, e25-e36		34
128	Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. <i>Value in Health</i> , 2012 , 15, 835-42	3.3	371

127	Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. <i>Value in Health</i> , 2012 , 15, 796-803	3.3	367
126	The effect of deprivation and HbA1c on admission to hospital for diabetic ketoacidosis in type 1 diabetes. <i>Diabetologia</i> , 2012 , 55, 2356-60	10.3	29
125	Nurse led versus lay educators support for those with asthma in primary care: a costing study. <i>BMC Pulmonary Medicine</i> , 2012 , 12, 52	3.5	3
124	Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. <i>Medical Decision Making</i> , 2012 , 32, 722-32	2.5	402
123	Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information. <i>Value in Health</i> , 2011 , 14, 205-18	3.3	25
122	Predicting EQ-5D values using the SGRQ. <i>Value in Health</i> , 2011 , 14, 354-60	3.3	64
121	Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis. <i>Value in Health</i> , 2011 , 14, 15-23	3.3	11
120	Power and sample size for cost-effectiveness analysis: fFN neonatal screening. <i>Contemporary Clinical Trials</i> , 2011 , 32, 893-901	2.3	15
119	How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2) LEN statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011 , 66, 765-74	8.3	57
118	Inpatient costs for people with type 1 and type 2 diabetes in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetologia</i> , 2011 , 54, 2000-8	10.3	23
117	Trends in incidence and in short term survival following a subarachnoid haemorrhage in Scotland, 1986-2005: a retrospective cohort study. <i>BMC Neurology</i> , 2011 , 11, 38	3.1	15
116	Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting?. <i>Trials</i> , 2011 , 12,	2.8	9
115	Review of statistical methods for analysing healthcare resources and costs. <i>Health Economics (United Kingdom)</i> , 2011 , 20, 897-916	2.4	440
114	Perioperative and long-term outcomes following aortic valve replacement: a population cohort study of 4124 consecutive patients. <i>European Journal of Cardio-thoracic Surgery</i> , 2011 , 40, 1508-14	3	5
113	Achieved levels of HbA1c and likelihood of hospital admission in people with type 1 diabetes in the Scottish population: a study from the Scottish Diabetes Research Network Epidemiology Group. <i>Diabetes Care</i> , 2011 , 34, 1992-7	14.6	27
112	One-year outcomes and a cost-effectiveness analysis for smokers accessing group-based and pharmacy-led cessation services. <i>Nicotine and Tobacco Research</i> , 2011 , 13, 135-45	4.9	49
111	Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. <i>BMJ, The</i> , 2011 , 343, d4044	5.9	123
110	SCOT: Short Course Oncology Therapy--a comparison of 12 and 24 weeks of adjuvant chemotherapy in colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, e14145-e14145	2.2	2

109	Transportability of comparative effectiveness and cost-effectiveness between countries. <i>Value in Health</i> , 2010 , 13 Suppl 1, S22-5	3.3	13
108	Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UK. <i>British Journal of Cancer</i> , 2010 , 103, 776-86	8.7	30
107	Outcome measurement in economic evaluations of public health interventions: a role for the capability approach?. <i>International Journal of Environmental Research and Public Health</i> , 2010 , 7, 2274-89	4.6	80
106	Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study. <i>European Respiratory Journal</i> , 2010 , 35, 532-9	13.6	54
105	Estimating the impact of stroke unit care in a whole population: an epidemiological study using routine data. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, 1301-5	5.5	34
104	A systematic review of continuous performance task research in children prenatally exposed to alcohol. <i>Alcohol and Alcoholism</i> , 2010 , 45, 30-8	3.5	15
103	An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. <i>European Journal of Heart Failure</i> , 2010 , 12, 66-74	12.3	15
102	Appropriate cohorts for cost-effectiveness analysis: to mix or not to mix?. <i>Medical Decision Making</i> , 2010 , 30, 424-5	2.5	3
101	Access with evidence development in the UK: past experience, current initiatives and future potential. <i>Pharmacoeconomics</i> , 2010 , 28, 163-70	4.4	28
100	International comparison of comparative effectiveness research in five jurisdictions: insights for the US. <i>Pharmacoeconomics</i> , 2010 , 28, 813-30	4.4	32
99	Reply to Evidence is still required for treatment as prevention for riskier routes of HIV transmission. <i>Aids</i> , 2010 , 24, 2892-2893	3.5	1
98	Expanding access to HAART: a cost-effective approach for treating and preventing HIV. <i>Aids</i> , 2010 , 24, 1929-35	3.5	51
97	Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. <i>European Journal of Health Economics</i> , 2010 , 11, 427-34	3.6	79
96	Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes. <i>Quality of Life Research</i> , 2010 , 19, 323-33	3.7	14
95	Temporal trends in hospitalisation for stroke recurrence following incident hospitalisation for stroke in Scotland. <i>BMC Medicine</i> , 2010 , 8, 23	11.4	24
94	Using an iterative approach to economic evaluation in the drug development process. <i>Drug Development Research</i> , 2010 , 71, 470-477	5.1	9
93	Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration. <i>Journal of Ophthalmology</i> , 2009 , 2009, 540431	2	
92	Age- and sex-specific trends in fatal incidence and hospitalized incidence of stroke in Scotland, 1986 to 2005. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009 , 2, 475-83	5.8	19

91	Cost-effectiveness of lifestyle modification in diabetic patients. <i>Diabetes Care</i> , 2009 , 32, 1453-8	14.6	44
90	Comparative effectiveness research through the looking glass. <i>Medical Decision Making</i> , 2009 , 29, NP6-82.5		5
89	Sex differences in incidence, mortality, and survival in individuals with stroke in Scotland, 1986 to 2005. <i>Stroke</i> , 2009 , 40, 1038-43	6.7	60
88	Cost-effectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. <i>Addiction</i> , 2009 , 104, 317-25	4.6	37
87	Health Economics in Asthma and COPD 2009 , 751-760		
86	Assessing the economic merits of managing cytomegalovirus infection in organ and stem cell transplantation. <i>Journal of Medical Economics</i> , 2009 , 12, 68-76	2.4	
85	Acute rejection and chronic nephropathy: a systematic review of the literature. <i>Transplantation</i> , 2009 , 87, 1330-9	1.8	47
84	The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. <i>Value in Health</i> , 2008 , 11, 527-38	3.3	100
83	Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). <i>Value in Health</i> , 2008 , 11, 886-97	3.3	185
82	Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 105	3	86
81	Value based pricing for NHS drugs: an opportunity not to be missed?. <i>BMJ, The</i> , 2008 , 336, 251-4	5.9	135
80	Health technology assessment in the cost-disutility plane. <i>Medical Decision Making</i> , 2008 , 28, 172-81	2.5	38
79	Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. <i>Archives of Internal Medicine</i> , 2008 , 168, 71-9		61
78	Pharmacoeconomics in COPD: lessons for the future. <i>International Journal of COPD</i> , 2008 , 3, 71-88	3	14
77	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007 , 12, 56-8	2.4	122
76	Meta-analysis of mixed treatment comparisons at multiple follow-up times. <i>Statistics in Medicine</i> , 2007 , 26, 3681-99	2.3	80
75	Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2007 , 114, 1352-62	3.7	30
74	Cost effectiveness of perindopril in reducing cardiovascular events in patients with stable coronary artery disease using data from the EUROPA study. <i>Heart</i> , 2007 , 93, 1081-6	5.1	44

73	How cost-effective is screening for abdominal aortic aneurysms?. <i>Journal of Medical Screening</i> , 2007 , 14, 46-52	1.4	46
72	Searching for a threshold [Not so] <i>Journal of Health Services Research and Policy</i> , 2007 , 12, 190-191	2.4	2
71	The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. <i>Journal of Health Services Research and Policy</i> , 2007 , 12, 11-7	2.4	22
70	Recombinant erythropoietin for chemotherapy-related anaemia: economic value and health-related quality-of-life assessment using direct utility elicitation and discrete choice experiment methods. <i>Pharmacoeconomics</i> , 2007 , 25, 223-37	4.4	30
69	Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. <i>Health Economics (United Kingdom)</i> , 2006 , 15, 1-4	2.4	71
68	Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. <i>BMJ, The</i> , 2006 , 333, 1145	5.9	70
67	Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. <i>European Heart Journal</i> , 2006 , 27, 796-801	9.5	49
66	Pharmacoeconomics and pharmacoepidemiology: curious bedfellows or a match made in heaven?. <i>Pharmacoeconomics</i> , 2006 , 24, 1079-86	4.4	16
65	2006 ,		136
64	Cost-effectiveness of asthma control: an economic appraisal of the GOAL study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006 , 61, 531-6	9.3	64
63	Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data. <i>Value in Health</i> , 2006 , 9, 227-35	3.3	27
62	Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. <i>Lancet, The</i> , 2005 , 365, 1779-85	4.0	90
61	PIN15 IMPACT ON QUALITY OF LIFE OF HEALTH STATES INDUCED BY CHRONIC HEPATITIS B INFECTION: ESTIMATES FROM UNINFECTED AND INFECTED PERSONS IN THE UK. <i>Value in Health</i> , 2005 , 8, A60	3.3	2
60	Incorporation of uncertainty in health economic modelling studies. <i>Pharmacoeconomics</i> , 2005 , 23, 529-36	4.4	45
59	Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. <i>Pharmacoeconomics</i> , 2005 , 23, 619-37	4.4	104
58	Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization. <i>Respiratory Medicine</i> , 2005 , 99, 1534-45	4.6	16
57	Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. <i>American Heart Journal</i> , 2005 , 149, 434-43	4.9	71
56	Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. <i>Value in Health</i> , 2005 , 8, 521-33	3.3	481

55	Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. <i>Value in Health</i> , 2005 , 8, 1-2	3.3	119
54	Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models. <i>Health Economics (United Kingdom)</i> , 2005 , 14, 471-85	2.4	81
53	Parametric modelling of cost data: some simulation evidence. <i>Health Economics (United Kingdom)</i> , 2005 , 14, 421-8	2.4	75
52	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. <i>Health Economics (United Kingdom)</i> , 2005 , 14, 339-47	2.4	313
51	Unfinished symphony: a tribute to the life and career of Bernie O'Brien (1959-2004). <i>Medical Decision Making</i> , 2004 , 24, 538-44	2.5	0
50	Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. <i>Health Economics (United Kingdom)</i> , 2004 , 13, 461-75	2.4	220
49	Cost-effectiveness acceptability curves--facts, fallacies and frequently asked questions. <i>Health Economics (United Kingdom)</i> , 2004 , 13, 405-15	2.4	634
48	The use of probabilistic decision models in technology assessment : the case of total hip replacement. <i>Applied Health Economics and Health Policy</i> , 2004 , 3, 79-89	3.4	34
47	A glossary of economic terms. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 563-5	2.2	4
46	Statistical approaches to handling uncertainty in health economic evaluation. <i>European Journal of Gastroenterology and Hepatology</i> , 2004 , 16, 551-61	2.2	52
45	Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. <i>Journal of Clinical Gastroenterology</i> , 2004 , 38, S179-86	3	17
44	Missing... presumed at random: cost-analysis of incomplete data. <i>Health Economics (United Kingdom)</i> , 2003 , 12, 377-92	2.4	232
43	Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework. <i>Medical Decision Making</i> , 2003 , 23, 341-50	2.5	124
42	A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. <i>Medical Decision Making</i> , 2003 , 23, 252-64	2.5	4
41	Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 2002 , 11, 415-30	2.4	372
40	Cost-effectiveness and cost-utility of long-term management strategies for heartburn. <i>Value in Health</i> , 2002 , 5, 312-28	3.3	22
39	Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods. <i>Statistical Methods in Medical Research</i> , 2002 , 11, 455-68	2.3	176
38	Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. <i>Annual Review of Public Health</i> , 2002 , 23, 377-401	20.6	299

37	Development of an economic model to assess the cost effectiveness of asthma management strategies. <i>Pharmacoeconomics</i> , 2002 , 20, 183-94	4.4	68
36	Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. <i>Medical Decision Making</i> , 2002 , 22, 290-308	2.5	117
35	The death of cost-minimization analysis?. <i>Health Economics (United Kingdom)</i> , 2001 , 10, 179-84	2.4	316
34	Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. <i>Health Economics (United Kingdom)</i> , 2001 , 10, 675-80	2.4	83
33	The Design and Analysis of Stochastic Cost-Effectiveness Studies for the Evaluation of Health Care Interventions. <i>Drug Information Journal</i> , 2001 , 35, 1455-1468		9
32	Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. <i>American Heart Journal</i> , 2001 , 142, 537-43	4.9	34
31	Empirical treatment or prompt endoscopy. <i>Lancet, The</i> , 2001 , 357, 1366		40
30	Quantifying stochastic uncertainty and presenting results of cost-effectiveness analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2001 , 1, 25-36	2.2	71
29	A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes. <i>International Journal of Technology Assessment in Health Care</i> , 2001 , 17, 69-82	1.8	48
28	Centre-specific or average unit costs in multi-centre studies? Some theory and simulation. <i>Health Economics (United Kingdom)</i> , 2000 , 9, 191-8	2.4	37
27	Cost effectiveness of initial endoscopy for dyspepsia in patients over age 50 years: a randomised controlled trial in primary care. <i>Lancet, The</i> , 2000 , 356, 1965-9	4.0	104
26	Handling uncertainty in cost-effectiveness models. <i>Pharmacoeconomics</i> , 2000 , 17, 479-500	4.4	544
25	A Bayesian approach to stochastic cost-effectiveness analysis. <i>Health Economics (United Kingdom)</i> , 1999 , 8, 257-61	2.4	171
24	Constructing confidence intervals for cost-effectiveness ratios: an evaluation of parametric and non-parametric techniques using Monte Carlo simulation. <i>Statistics in Medicine</i> , 1999 , 18, 3245-62	2.3	94
23	Handling uncertainty in economic evaluations of healthcare interventions. <i>BMJ: British Medical Journal</i> , 1999 , 319, 635-8		123
22	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. <i>Health Economics (United Kingdom)</i> , 1998 , 7, 723-40	2.4	275
21	An introduction to Markov modelling for economic evaluation. <i>Pharmacoeconomics</i> , 1998 , 13, 397-409	4.4	578
20	The distribution of health care costs and their statistical analysis for economic evaluation. <i>Journal of Health Services Research and Policy</i> , 1998 , 3, 233-45	2.4	180

19	Treatment of early-stage breast cancer in the elderly: a health-outcome-based approach. <i>Medical Decision Making</i> , 1998 , 18, 213-9	2.5	39
18	The costs and benefits of primary total hip replacement. How likely are new prostheses to be cost-effective?. <i>International Journal of Technology Assessment in Health Care</i> , 1998 , 14, 743-61	1.8	18
17	Prevention of mother-to-child transmission of HIV-1 infection: alternative strategies and their cost-effectiveness. <i>Aids</i> , 1998 , 12, 1381-8	3.5	30
16	Power and sample size calculations for stochastic cost-effectiveness analysis. <i>Medical Decision Making</i> , 1998 , 18, S81-92	2.5	54
15	Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane 1998 , 7, 723		5
14	Interferon- α in Hepatitis C: The Authors Reply. <i>Pharmacoeconomics</i> , 1997 , 11, 491-492	4.4	
13	Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. <i>Health Economics (United Kingdom)</i> , 1997 , 6, 327-40	2.4	583
12	Trying to do better than average: a commentary on 'statistical inference for cost-effectiveness ratios'. <i>Health Economics (United Kingdom)</i> , 1997 , 6, 491-5	2.4	21
11	Commentary: Markov models of medical prognosis. <i>BMJ: British Medical Journal</i> , 1997 , 314, 354-5		7
10	Interferon-alpha in hepatitis C. Dosage, costs and benefits. <i>Pharmacoeconomics</i> , 1996 , 10, 205-9	4.4	3
9	A model for analyzing the cost of main clinical events after cardiac transplantation. <i>Transplantation</i> , 1996 , 62, 615-21	1.8	18
8	Sensitivity analysis in economic evaluation: a review of published studies. <i>Health Economics (United Kingdom)</i> , 1995 , 4, 355-71	2.4	81
7	Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. <i>Health Economics (United Kingdom)</i> , 1994 , 3, 95-104	2.4	386
6	The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C. <i>Medical Journal of Australia</i> , 1994 , 160, 268-272	4	32
5	Cost effectiveness of interferon in chronic active hepatitis C. <i>Medical Journal of Australia</i> , 1994 , 161, 170-170	4	1
4	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 4 , 108	4.8	4
3	Handling Uncertainty in Economic Evaluation 314-337		8
2	Cost-effectiveness of oral versus intravenous antibiotics (OVIVA) in patients with bone and joint infection: evidence from a non-inferiority trial. <i>Wellcome Open Research</i> , 4 , 108	4.8	1

- 1 Reporting Guidelines for Health Economic Evaluations: BMJ Guidelines for Authors and Peer Reviewers of Economic Submissions 296-305